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Stroke is a leading cause of disability and death worldwide. Numerous therapeutics applied acutely after
stroke have failed to improve long-term clinical outcomes. An emerging direction is nutritional inter-
vention with omega-3 polyunsaturated fatty acids acting as disease-modifying factors and targeting
post-stroke disabilities. Our previous studies demonstrated that the omega-3 precursor, alpha-linolenic
acid (ALA) administrated by injections or dietary supplementation reduces stroke damage by direct
neuroprotection, and triggering brain artery vasodilatation and neuroplasticity. Successful translation of
putative therapies will depend on demonstration of robust efﬁcacy on common deﬁcits resulting from
stroke like loss of motor control and memory/learning. This study evaluated the value of ALA as
adjunctive therapy for stroke recovery by comparing whether oral or intravenous supplementation of
ALA best support recovery from ischemia. Motor and cognitive deﬁcits were assessed using rotarod, pole
and Morris water maze tests. ALA supplementation in diet was better than intravenous treatment in
improving motor coordination, but this improvement was not due to a neuroprotective effect since
infarct size was not reduced. Both types of ALA supplementation improved spatial learning and memory
after stroke. This cognitive improvement correlated with higher survival of hippocampal neurons. These
results support clinical investigation establishing therapeutic plans using ALA supplementation.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Annually, 15 million people worldwide suffer a stroke. Of these,
30% die and another 30% are left permanently disabled, placing arnu Ammonis; DAB, 3,30-dia-
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bral artery occlusion; MWM,
onal Institutes of Health; PBS,
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ble synaptosomal-associated
., United States.
Moleculaires et Cellulaires,
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Ltd. This is an open access article utremendous burden on family and community. A stroke occurs on
average every 40 and 90 s, in the United States and Europe,
respectively (Go et al., 2014; Gustavsson et al., 2011). The estimated
cost of stroke for 2010 was approximately $74 billion and V64
billion, respectively (Gustavsson et al., 2011; Lloyd-Jones et al.,
2010). Apart for thrombolysis e for which inclusion criteria are
fairly restrictive - clinical trials for the treatment of acute ischemic
stroke have been almost all unsuccessful, leaving patients with an
extremely limited repertoire of therapeutic opportunities.
Nevertheless, improvements in population health e particularly
in the control of major risk factors of stroke such as hypertension,
diabetes, high cholesterol levels and smoking - over the past de-
cades have contributed to reduced stroke mortality. Unfortunately,
stroke remains a substantial problem, since mortality represents, at
best, a third of annual ﬁrst-ever strokes. Indeed, in 2007 thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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30e60% of these were estimated to be dependent in some aspect of
daily living. These survivors have a high level of disability with
more than 50% of patients being left with a residual motor or
cognitive/amnesic deﬁcit. Stroke burden was calculated to be
approximately 51 million disability-adjusted life years [DALYs]
(Johnston et al., 2009; Strong et al., 2007). Therefore, reducing long-
term disability by improving recovery would have a substantial
impact.
The major stroke-induced impairments are motor and cognitive
deﬁcits. Motor impairment is characterized by a loss or limitation of
function in muscle control or a limitation in mobility (walking/
gaiting) (Jorgensen et al., 1995). In 80% of patients, altered control of
the face, arm, and leg of one body side are described as typical
symptoms of stroke (Langhorne et al., 2009). Cognitive impairment
affects multiple domains, including attention, executive function,
visuo-spatial ability, memory and language. As well, focal disorders
such as aphasia and neglect are common, as are more diffuse ab-
normalities such as reduced information processing and executive
dysfunction (Cumming et al., 2013).
Confronted with a lack of treatment options, various strategies
have been developed to enhance motor recovery, ranging from
pharmacological agents prescribed against hypertension, depres-
sion or Alzheimer disease, to exercise training (treadmill …) and
even to repetitive transcranial magnetic stimulation (rTMS)
(Calautti and Baron, 2003; Cramer, 2008; Langhorne et al., 2011).
Increasing physical activity and rTMS are also known to improve
cognition (Cumming et al., 2013). In cognitive and memory post-
stroke rehabilitation, the efﬁciency of task-speciﬁc training re-
mains uncertain mainly due to a paucity of studies (Lincoln et al.,
2000; Nair and Lincoln, 2007). Interestingly, most of the motor
and cognitive rehabilitation approaches have been shown retro-
spectively to target neural plasticity and to increase levels of
neurotropic factors in the brain (Di Pino et al., 2014; Johansson,
2011).
An emerging preclinical concept to support the recovery of body
and brain after stroke is nutrition. Nevertheless how nutrition may
affect stroke recovery has not yet been intensely investigated,
which is surprising given its great inﬂuence as risk factor (Hankey,
2012). Most interventions showing that nutrition could improve
the recovery of neurocognitive functions in ischemic stroke pa-
tients have been based on protein supplementation provided to
counteract stroke-induced protein synthesis depression or
malnutrition (Aquilani et al., 2010). Apart from supplementation
with vitamins, which may reduce oxidative damage after acute
ischemic stroke (B and E groups) or have statin-like effects (Vitamin
D) nutritional intervention in stroke patients has been investigated
to a limited extent (Pilz et al., 2011).
Severe deﬁciencies identiﬁed in omega-3 polyunsaturated fatty
acids (PUFAs), both in the form of alpha-linolenic acid (ALA) and the
long chain derivatives eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA), stand out as risk factors for cardiovascular
and cerebral diseases (Riediger et al., 2009; Kris-Etherton et al.,
2002). A body of preclinical studies have documented omega-3
PUFAs supplementation additional beneﬁts in the context of
stroke: that as an effective and pleiotropic neuroprotective
approach against ischemia (for review (Blondeau and Tauskela,
2013; Gouix et al., 2014; Nguemeni et al., 2013)). As well, ﬁsh-oil
PUFAs supplemented in diet prior to ischemia was also found
exerting a beneﬁcial effect on spatial memory deﬁcits that was not
correlated with any beneﬁt in hippocampal neurons survival sug-
gesting that PUFAs may also promote stroke recovery (Plamondon
and Roberge, 2008). During the last decade, we identiﬁed pleio-
tropic abilities of ALA to trigger multi-cellular and mechanistically
diverse responses, resulting in neuronal protection from stroke(see: (Blondeau, 2016; Blondeau et al., 2015; Blondeau and
Tauskela, 2013; Nguemeni et al., 2013)). In a mouse model of
stroke, a subchronic post-treatment consisting of three sequential
injections of ALA enhanced animal survival rates by three-fold, ten
days following ischemia (Blondeau et al., 2009c). Several clinical
studies indicated that i.v. perfusion of long chain PUFAs, delivered
as parenteral supplementation with a 10% ﬁsh oil emulsion
(Omegaven, Fresenius-Kabi), may reduce mortality, antibiotic use,
and length of hospital stay in different diseases (Heller et al., 2002,
2006). While it seems intuitive that beneﬁcial effects related to ﬁsh
oil doses may be reliant on the pathology phenotype, it was
tempting to speculate some value of omega-3 fatty acid as
adjunctive therapy for stroke recovery. ALA supplementation either
as an i.v. treatment or as enriched-diet also enhances brain plas-
ticity and improves neurite growth and remodeling in hippocampal
neurons (a main site for memory formation) (Blondeau et al.,
2009a; Venna et al., 2009), suggesting that ALA may represent an
excellent nutraceutical strategy to promote post-stroke recovery.
To provide insight into the potential of ALA on post-stroke
rehabilitation, we explored whether ALA supplementation deliv-
ered by i.v. subchronic treatment or modiﬁcation of the daily diet
could facilitate recovery of motor and cognitive functions after
stroke in the 30 min MCAo model (which has been described as the
gold standard for characterization of long-term function in mice
(Balkaya et al., 2013)). We ﬁrst evaluated the effect of the ALA
supplementation on the ischemic brain lesion and long-term
mortality rate. We further determined motor deﬁcits by the
rotarod and pole test and cognitive deﬁcits using the Morris Water-
Maze test. Finally, we evaluated the effect of ALA supplementation
on selective neuronal lesions that are known to important for
stroke rehabilitation.
2. Material and methods
2.1. Animals, diets and treatments
Male 4-week old C57BL/6 J mice (Janvier France Breeding) were
housed under standardized conditions and received care according
to the policies of European Community Directive 86/609/EEC. The
Institutional Animal Care and Use Committees (CIEPAL) approved
the study (French Authorization N06-118). Mice were fed a regular
rodent diet (SAFE, France) with an ALA concentration of 0.25%
(0.25 g in 100 g of regular diet, a proportion matching the ‘‘murine’’
recommended intake (Bourre et al., 1993; Pudelkewicz et al., 1968))
or an experimental diet enriched in ALA by a factor of three
compared to regular chows, for 6 weeks. The content of proteins,
minerals, micronutrients, vitamins and the metabolizable energy
density provided by the different formulations are as previously
described (Nguemeni et al., 2010). Brieﬂy, in the ALA enriched diet
(ALA-diet) lipids from rapeseed oil accounts for 10% and ALA for
0.75% by weight. The ALA-diet did not contain any EPA or DHA, in
contrast to the regular chow. Body weight, and water and food
consumption were monitored through the entire experiments
(Nguemeni et al., 2010). With respect to parenteral supplementa-
tion (ALA, Enzo Life Sciences), animals were injected in the penil
vein 2 h, 3 d, 7 d, 10 d, 14 d, 17 d and 21 d after the occlusion of the
middle cerebral artery (MCAo). The timing and dose (500 nmol/kg
as a bolus of 50 ml) selected for sequential injections of ALA were
based on our previous studies in themouse model of focal ischemia
induced by a longer duration of MCAo (Blondeau et al., 2009c;
Heurteaux et al., 2006).
2.2. Middle cerebral artery occlusion
Focal ischemia was induced by a 30 min of transitory MCAo
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Nguemeni et al., 2010). Cerebral blood ﬂow measurements by
laser Doppler ﬂowmetry (Perimed, Craponne, France) conﬁrmed an
ischemic occlusion (reduced by 85% of baseline) during MCAo and
restoration of blood ﬂow during reperfusion, conditions required
for mice being included in the study. Physiological parameters,
including weight and survival rate were assessed (Nguemeni et al.,
2010).
2.3. Evaluation of brain ischemic lesions
The infarct volume was determined 24 h after MCAo on coronal
frozen brain sections stained using a solution of 1% cresyl violet in
0.25% acetic acid. The striatal and cortical areas of infarction were
measured on each section using a computer image analysis system
and corrected for brain edema according (Golanov and Reis, 1995).
Infarct volume (in mm3) was calculated by a linear integration of
the corrected lesion areas (Blondeau et al., 2009b; Nguemeni et al.,
2010). Late infarct consolidation was assessed 21 days post-stroke
by NeuN (neuronal nuclei) immunohistochemistry. Brieﬂy, brain
sections were incubated overnight with anti-NeuN antibodies
(mouse monoclonal, 1:200; Chemicon) and a 3-stage avidin-biotin
methodwith corresponding biotinylated secondary antibody. NeuN
expression was visualized with 3,30-diaminobenzidine (DAB as
chromogene). NeuN-positive cells were counted in the cortex and
striatum, including the caudate-putamen area at the level of the
lesion (bregma level 0.3 mm; magniﬁcation  40) (Blondeau et al.,
2009b; Heurteaux et al., 2006; Nguemeni et al., 2010). Data were
expressed as number of NeuN-positive cells per mm2.
In a separate group ofmice, we blindly assessed cellular status at
3 weeks post-MCAo. Tissue characteristics were quantiﬁed by
measuring ipsilateral and contralateral hemispheric volumes and
calculating tissue loss and atrophy using coronal cryosections
stained with cresyl violet (Lee et al., 2014). Calculations of neuronal
density of hippocampal CA1, CA2 and CA3 (Cornu Ammonis) sub-
ﬁelds were evaluated on coronal sections of the dorsal hippocam-
pus stained with cresyl violet, corresponding to brain sections
located between 1.46 and 2.18 mm posterior to bregma. The
number of living neurons in the stratum pyramidal within the CA1,
CA2 and CA3 area (mm2 measured with a digitizer) was counted
using a Leica DMD108 microscope.
2.4. Behavioral tests
2.4.1. Rotarod
The rotarod test has been reported to be effective for evaluating
motor coordination and balance alterations after MCAo in rodent
(Rogers et al., 1997). The rotarod apparatus (Ugo Basile, France)
consists of a striated rod (diameter 3 cm) subdivided into 5 areas of
5 cmwidth by disks 25 cm in diameter. The days preceding the day
of surgery, mice were trained on the rotarod for 5 min at a constant
speed (4 rpm) that was followed by a single trial on the rotarod
accelerating from 4 to 40 rpm over a period of 10 min (maximal
scores at 10 min) after 30 min rest. The latency of mice to fall from
the rotarod was recorded and this score was considered as the
baseline (pre-operative score). Mice were tested during the ﬁrst
week post-stroke at Day 2, 3, 4, 7, to detect the effect of ALA sup-
plementation on motor deﬁcits (Fig. 2). Rotarod test was also car-
ried out at Day 10, 14 and 21 post-MCAo to conﬁrm the occurrence
of spontaneous recovery of motor impairments (Freret et al., 2011),
when the effect of ALA supplementation on spatial memory using
the Morris water-maze task was studied (data not shown).
2.4.2. Pole test
The vertical pole test is a motor task reported to be effective forevaluating motor coordination, forelimb strength, and ability to
grasp and balance in MCAo mice (Ji et al., 2009; Matsuura et al.,
1997). A vertical wood pole of 50 cm was covered with tape to
create a rough surface. The animal was placed with the head facing
upward near the top of the pole. The time taken tomake a complete
U-turn downward (time to turn) and the total time to touch the
ground with all four paws were recorded. If unable to turn
completely, the time to reach the ground was also included in the
time to turn. Each animal was tested over 5 trials and the average
score was recorded as the ﬁnal pole test score.2.4.3. Morris Water-Maze (MWM) test
The water-maze test is a spatial memory task reported to be
effective for evaluating learning and memory deﬁcits after MCAo.
Experiments were closely adapted from previously published pro-
tocols withminor modiﬁcations (Quintard et al., 2011;Winter et al.,
2004). A 120-cm-diameter, 60-cm-high circular swimming pool
was ﬁlled to a depth of 32 cm with 21 ± 2 C opaque water. Visible
cueswere placed on thewalls of the pool remained in ﬁxed position
throughout experiments. A clear plexiglas platformwith a diameter
of 11 cm was submerged 1 cm below the water level. Swimming
performance (eg, path, speed, latency, distance) was tracked with a
computer-based system (ANYmaze, Smart, Bioseb, France). A full
experiment had two phases: a learning period (place task) for 4
consecutive days and a probe trial on day 5, two and three weeks
after ischemia. Phase 1: for the learning period, each mouse was
subjected to four trials a day in a pool divided into four equal hy-
pothetical quadrants. The position of platform was constant
throughout the training session, while the starting position on each
of the four training trials day was changed (Rehni and Singh, 2012).
If a mouse did not ﬁnd the platformwithin 60 s, it was guided to the
platform. After reaching the platform, mice were allowed to stay
there for 30 s. Phase 2: for the probe trial, mice were allowed to
swim freely for 60 s in the absence of the platform. The time spent
in each quadrant and crosses through the location of the former
platform was measured. Absence of visual or motor impairment
was controlled without speciﬁc visual cues placed around the
outside of the tank but a visible platform (identiﬁed by an object on
the platform). This test was performed the day after the probe trial.2.5. Lipid extraction and fatty acid analysis
Fatty acids were extracted from cortex samples and analyzed as
described previously (Awada et al., 2013). Tissue fatty acid methyl
ester peak identiﬁcation was performed by comparison with peak
retention times of a 30-component methyl ester standard (Sigma).
The concentration of each fatty acid was determined by calculating
the areas of peaks.2.6. Statistical analysis
Statistics were carried out in GraphPad Prism. Data were
expressed as mean ± SEM. Survival curves were compared by log-
rank test. Statistical analysis of differences between groups was
performed by using unpaired t-test or ANOVA. Where F ratios were
signiﬁcant, statistical analyses were extended and post-hoc com-
parisons were made by using Tukey's test for multiple comparison
tests. Pearson correlation analysis was used to study the correlation
between the time in target zone and the hippocampal neuronal
density. The level of signiﬁcance was set at p < 0.05.
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3.1. ALA dietary supplementation is superior to i.v. treatment in
improving motor coordination, but does not correlate with neuronal
protection 3 days post-MCAo
During the 3 weeks following a 30 min MCAo, the mortality rate
was not inﬂuenced by ALA supplementation achieved through diet
modiﬁcation or i.v. subchronic treatment (Fig. 1A and B). Mortality
evaluated 7 days post-MCAo was 25% and 16% for mice fed the
regular diet and the ALA-diet, respectively, which was not signiﬁ-
cantly different from the 16% mortality observed when animalsFig. 1. Effects of a-linolenic acid supplementation on long-term survival, infarct size and bo
affected by ALA supplementation, by modiﬁcation of the daily diet (A) or by i.v. subchronic t
treated and ALA-treated groups, respectively). Twenty-four hours after 30 min MCAo, the
mentation (C and D). Data are represented by mean ± SEM (n ¼ 11 per group). (E and F) Du
weight loss was lower in animal feds the ALA-diet following 30 min of MACo. During the cog
represented by boxes, median, and interquartile range; whiskers, minemax; þ, mean (*p <were i.v. treated with ALA. Quantitative assessment of infarct vol-
umes 24 h reperfusion after 30 min MCAo revealed that mice fed
regular or ALA-diet displayed similar cerebral infarction volumes
(29.2 ± 6.4 mm3 versus 28.8 ± 5.5 mm3, Fig. 1C). ALA treatment by
i.v. subchronic treatment did not inﬂuence cerebral infarction
induced by 30 min MCAo. The infarct volumes were of
26.7 ± 2.0 mm3 and 25.5 ± 2.2 mm3, respectively in the vehicle and
ALA treated-group (Fig. 1D).
The percentage change in body weights post-MCAo compared
with values recorded immediately prior to undergoing MCAo were
used as primary indicators of general well-being. Mice were
weighed daily for 7 days post-surgery for the short-term study anddy weight after 30 min MCAo. Long-term survival rate after 30 min of MCAo was not
reatment (B), (n ¼ 35, n ¼ 35, n ¼ 30 and n ¼ 28 in the regular diet, ALA-diet, vehicle-
infarct volume was similar between all groups, showing no effect of the ALA supple-
ring the ﬁrst week post-MCAo corresponding to the period of motor deﬁcit evaluation,
nitive deﬁcit evaluation, animals did not differ in weights between each group. Data are
0.05; **p < 0.01; n > 30 per group; unpaired t-test).
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over the ﬁrst 2 days post-MCAo (Fig. 1E and F) after which they
began to regain weight until reaching their baseline after a week.
Interestingly, mice fed the ALA-diet gained weight at a signiﬁcantly
faster rate than mice fed the regular-diet (Fig. 1E), while there was
no differences in weight gain between groups treated with sub-
chronic treatment (Fig. 1F). In the longer-term study, weight did not
signiﬁcantly differ between experimental groups 21 days post-
MCAo.
To determine whether daily increased intake of ALA improved
functional recovery after stroke, mice were preventively fed an
ALA-diet for 6 weeks before MCAo. Pre-operative performance in
the rotarod test did not differ signiﬁcantly between animals fed the
regular or ALA-diet. As expected, postoperative performance of
MCAo animals was signiﬁcantly impaired (Fig. 2A). Spontaneous
recovery from themotor coordination impairment was faster in the
group fed the ALA-diet compared to the animals fed the regular diet
(Fig. 2A). The post-MCAo performance of animals fed the ALA-diet
was signiﬁcantly improved by an average of 30% during the ﬁrst
week of recovery (2 W ANOVA: effect of group: F ¼ 21.53,
$$$p ¼ 0.00001). Single time-point analysis showed signiﬁcant
improvement in the performances on the rotarod in MCAo-mice
fed the ALA-diet as compared to animals fed the regular diet
(*p < 0.05, Fig. 2A). Compared to their pre-injury baseline on post-
MCAo day 2, 3, and 4, mice fed the ALA-diet were able to perform at
69%, 74%, and 100% (##p < 0.01, #p < 0.05) while mice fed the
regular diet only performed at 50%, 58%, and 76% (###p < 0.001,
##p < 0.01 and #p < 0.05), respectively. Surprisingly, the perfor-
mance of vehicle-treated animals and ALA-treated animals were
similar for the rotarod (Fig. 2B). Since the two sequential injections
of ALA were insufﬁcient in improving motor recovery, we then
explored whether the improvement of motor coordination caused
by the ALA-diet would be conﬁrmed in the pole test. Again, when
tested before MCAo, no difference was observed in this effect be-
tween the different diets. Between day 3e4 post-MCAo, the
average performance for the “time to turn” task of animals fed the
ALA-diet was signiﬁcantly improved as compared to animal fed the
regular diet (Fig. 2C, RM ANOVA: effect of group: F ¼ 4.35,
$$p¼ 0.0397). Single time-point analysis revealed that mice fed the
ALA-diet took less time to ﬁnish a complete turn only on day 3 post-
MCAo. The time to turn the head downwards was 2.9 ± 0.7 s for the
ALA-diet group compared to 6.6 ± 1.8 s for the regular diet group
(Fig. 2C, *p < 0.05). In the “latency to descend” task, MCAo animals
showed signiﬁcant impairment for 4 days (up to 14 days e not
shown) as compared to their pre-operative performance (Fig. 2D),
except at day 3 post-stroke for the mice fed the ALA-diet, which is
probably correlated with the marked reduction of their time to
turn. Overall, the ALA-diet did not have any signiﬁcant quantitative
effects on their rapidity to reach the ground, while the quality of the
descent was clearly visually abnormal (falling or slipping down
backward) in the group fed the regular diet (data not shown). This
predicted that analysis of the mice motion in ﬁne behavioral
assessment protocols to discern improvement in the range of mo-
tion, grasping and supination from compensation by postural ad-
justments may reveal improved recovery of the group fed the ALA-
diet (Murphy and Corbett, 2009). A detailed analysis of the neural
loss conﬁrmed that the improved motor recovery did not correlate
with better neuronal survival. Three days post-MCAo, brains of
animal fed the ALA and regular diet exhibited a similar subcortical
lesion as well as of the caudate putamen of the ipsilateral hemi-
sphere, characterized microscopically by the loss of 26% of the
NeuN-positive cells reﬂecting a marked neuronal destruction
(Fig. 2E and F). We further explored whether the disparity in efﬁ-
ciency between dietary supplementation and subchronic treatment
extended to cognitive recovery post-stroke.3.2. ALA supplementation improves spatial learning and memory
after MCAo
We ﬁrst evaluated the effects of an ALA-diet on functional re-
covery within 3 weeks after ischemic brain injury in a MWM
paradigm. The acquisition procedure did not reveal any signiﬁcant
difference between groups in swimming speed (Fig. 3A) or any
signiﬁcant reduction in the distance to ﬁnd the hidden platform
(Fig. 3B). Nonetheless, mice fed the ALA-diet had signiﬁcantly
improved latency to the hidden platform compared with mice fed
the regular diet (Fig. 3C), illustrating that the ALA-diet improved
learning performance of MCAo mice (2 W ANOVA: effect of group:
F ¼ 10.78, $$p ¼ 0.0014). Results of probe trial testing showed that
MCAo mice fed the ALA-diet performed signiﬁcantly better
compared with MCAo mice fed the regular diet. During the probe
trial, time in the target zone compared to the other three quadrants
was highest for mice fed the ALA-diet compared to the regular diet
(Fig. 3D, p < 0.05). During the 60 s probe trial, the number of
platform crossings was signiﬁcantly different betweenmice fed the
ALA- and regular diet (9.6 ± 2.0 and 3.1 ± 1.4, respectively, p < 0.05,
Fig. 3E). The ALA-diet group performance was signiﬁcantly better
during both periods (0e30 s and 30e60 s, p < 0.05, Fig. 3E). A
representative swim pattern of the probe test for each group clearly
demonstrated the difference in the search process 18 days post-
MCAo (Fig. 3F), whereas both groups exhibited similar perfor-
mance in visible platform tests (Fig. 3G).
Using the sameMWMparadigm to investigate the effect of ALA-
treatment on cognitive function, we observed similar levels of
improvement using the repeated ALA injections. No difference
between the ALA and vehicle-treated group was observed in
swimming speeds and distance to ﬁnd the hidden platform (not
shown), but the ALA-treatment displayed improved learning per-
formance (2WANOVA: effect of group: F¼ 4.96, $p¼ 0.04, Fig. 4A).
ALA-treated mice spend 25% more time in the target zone (Fig. 4B,
p < 0.05) compared to the vehicle-treated mice. Again, ALA sup-
plementation positively impacted the search process 18 days post-
MCAo (Fig. 4C), while ALA- and vehicle treated groups displayed
similar performance in visible platform tests (data not shown).
3.3. The ALA-induced cognitive improvement is supported by an
increased survival of neuronal cell of the hippocampus
To determine whether ALA improves cognition, we investigated
particular aspects of the brain lesion linked to spatial memory
deﬁcit 3 weeks post-MCAo.
At late time points, tissue loss and atrophy are accurate esti-
mations of the maturation of the ischemic lesion. The profound
(12%) tissue loss that was observed in the ipsilateral hemisphere of
the animals fed the regular diet was not detected in the ipsilateral
hemisphere of the animals fed the ALA-diet (#, p < 0.05) (Fig. 5A). A
profound (12%) tissue loss was also observed in the ipsilateral
hemisphere of the vehicle-injected animal. The atrophy was
reduced to 9% in the ALA-treated mice, but did not reach statistical
signiﬁcance (Fig. 5B). As a more straightforward endpoint, we
assessed neuronal density of the ipsilateral and contralateral
hippocampi. Thirty minutes MCAo induced signiﬁcant neuronal
damage in the hippocampal sector. Compared with their respective
contralateral sides, 45% and 30% of hippocampal neurons of animals
fed the regular diet and vehicle-treated groups, respectively, were
destroyed (not shown). An ALA-diet signiﬁcantly reduced neuronal
loss by 42% in the ipsilateral hippocampus compared with regular
diet when measured 3 weeks after ischemia (Fig. 5C). Similarly, the
ALA subchronic treatment also reduced neuronal loss throughout
the different hippocampal layers compared with the vehicle
treatment (Fig. 5C). The reduced number of necrotic cells observed
Fig. 2. Effects of a-linolenic acid supplementation on motor deﬁcits and neuronal loss induced by 30 min MCAo. (A) Mice fed the ALA-diet displayed better rotarod performance
within the ﬁrst week post-MCAo as compared to mice fed the regular diet. (B) The post-MCAo recovery of motor coordination was similar for the mice injected with ALA subchronic
treatment or vehicle. Data are represented by mean ± SEM (n ¼ 15 per group at each time point). *p < 0.05 versus respective control; #p < 0.05; ##p < 0.01; ###p < 0.001 versus
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and ALA subchronic treatment is highlighted on photomicrographs
shown in Fig. 5D. A correlation between hippocampal neuron loss
and time spent in the target zone was observed in the control
groups (regular diet and vehicle treated animals), which might
explain why ALA-supplemented animals presenting with less hip-
pocampal damage exhibited better spatial memory recovery
(Fig. 5E).
In addition, the analysis of cortical content of omega-3 PUFAs
indicated that the ALA-diet and a subchronic treatment of 3
sequential ALA injections did not change the content of the major
omega-3 fatty acids of the brain, DHA, compared to their respective
control (Fig. 5F). No difference was detected between the groups in
the overall n-6/n-3 PUFA ratio (Fig. 5G) and the omega-3 PUFA
fraction as well as in the proportions of saturated fatty acids,
monounsaturated fatty acids, and n-6 polyunsaturated fatty acids
(Fig. 5H). Altogether, these data suggest the existence of a protec-
tive effect of ALA on the different hippocampal layers, which cannot
be attributed to a potential bioconversion of ALA to DHA. This
sustained neuroprotection into late recovery stage may account for
the superior performance in the MWM cognitive test.
4. Discussion
Malnutrition is often observed in stroke patients because of
increased metabolic demands due in part to stroke complications
(Dennis et al., 2005). Consequently, on this basis alone, a nutritional
support should probably lead to improved clinical outcomes. Un-
fortunately, the effect of such nutritional intervention is still un-
clear for stroke patients and understudied in preclinical research.
The risk for severe deﬁciency in omega-3 PUFAs, known as risk
factors for stroke in the general population, often occurs during
post-stroke rehabilitation, while a body of preclinical evidence
documents the beneﬁts of ALA supplementation either as an i.v.
treatment or as enriched-diet in animal models of stroke
(Blondeau, 2016). Therefore we believe that an emerging direction
in nutritional intervention post-stroke stands in omega-3 ALA
supplementation. Since successful translation of putative therapies
will depend on demonstration of robust efﬁcacy on common deﬁ-
cits resulting from stroke like loss of motor control and memory/
learning, the central question of this study was to evaluate the in-
ﬂuence of nutritional support in omega-3 ALA in a murine model of
ischemic stroke. The 30 min MCAo produces a consistent selective
lesion (mainly striatal) with a low mortality in mice (Balkaya et al.,
2013), thereby allowing characterization of long-term functional
outcome. The infarct size and the related striatal damage observed
at 2 and 3 days post-MCAo were similar to those described for this
short-duration of ischemia (Katchanov et al., 2001; Kilic et al.). In a
clinical setting, the choice of nutritional support lies between oral
diet supplementation, enteral feeding (for patients who suffer for
dysphagia or other feeding difﬁculties, supplementation can be
achieved via a nasogastric or percutaneous endoscopic gastrostomy
tubing) or intravenous feeding (supplementation is delivered via
central venous line or by a less invasive option known as peripheral
total parenteral nutrition -TPN- via peripheral venous line). Inter-
estingly, a neuroprotective effect of ALA has been observed when
given by intravenous injection or after a 6-week feeding of an ALApre-MCAo performance and ($) indicates a group effect ($$$p < 0.001). (C and D) Similar re
forelimb strength post-MCAo in mice fed the ALA-diet. Data are represented by mean ± SEM
##p < 0.01; ###p < 0.001 versus pre-MCAo performance and ($) indicates a group effect ($$
3 days after 30 min MCAo illustrate that neuronal sparing was conﬁned to striatum. (F) Qu
caudate-putamen was not averted by consumption of the ALA-diet. This suggests that the im
brain region engaged in motor function. Data are represented by mean ± SEM (n ¼ 6 pe
applicable to all sections.enriched diet in the acute phase of ischemia in several animal
models of brain ischemia (Blondeau et al., 2001, 2009c, 2002b;
Heurteaux et al., 2006; Lauritzen et al., 2000; Nguemeni et al.,
2010). In addition, LC-omega-3 DHA also displayed neuro-
protective effects on acute and long-term ischemic brain damage
(Belayev et al., 2011), improving functional outcomes up to 5 weeks
after neonatal hypoxia/ischemia (Zhang et al., 2010). However the
effect of ALA on long-term brain damage and neurological func-
tional recovery was unknown.
In the 30 min MCAo model, where the infarct is mainly striatal,
no striking protective effect in reducing the lesion volume and the
mortality was detected. This result contrasts with our previous
observations in the more stringent model of 60 min MCAo, where
robust protection of the cortex was observed (Nguemeni et al.,
2010). Indeed, the evolution of loss of striatal neurons was
observed in all animal groups, being similar three days post-MCAo
betweenmice feed the ALA-enriched and regular diet. Similarly, the
neuroprotective effects of ALA observed with the single or sub-
chronic i.v. treatment in different models of brain ischemia
(Blondeau et al., 2002b, 2009c, 2003; Heurteaux et al., 2006;
Lauritzen et al., 2000) were not observed with the milder
ischemia of 30 min. It is known that the caudate-putamen, which is
more damaged by a mild stroke, has inherited motor and cognitive
functions (Katchanov et al., 2003), probably due to the in-
terconnections of this structure with several brain regions.
This study highlights the importance of diet supplementation in
the loss of body weight after stroke and its link with the recovery of
motor functions. While the exact etiology of weight loss after
ischemia is not completely understood, cerebral infarction itself
clearly represents one major cause. Interestingly, this work shows
that the extent of weight loss and the lesion volumes were similar
in all groups the ﬁrst post-operative day. Nevertheless, the time to
regain baseline levels (which usually depend on the duration and
severity of ischemia) was improved in the animals fed the ALA-diet
within the ﬁrst week post-stroke, which coincides with the spon-
taneous recovery of motor function. This information is of impor-
tance by providing an indication on how animals may better
recover from ischemia and even reﬂect a better prognostic for
functional outcome. The weight recovery after MCAo is a good and
independent indicator of the animal welfare. Indirectly, it shows
the general physiological condition of ischemic mice with an
extremely good correlation with clinical observations.
Weight loss after stroke is common even in patients in good
physical condition before stroke onset, for whom no less than a
quarter also undergo weight loss in the short and long term
(Jonsson et al., 2008). It is also associated with poor nutritional
status that is considered as a marker of poor outcome after stroke
(Collaboration, 2003). Consistent with clinical observations, MCAo-
induced weight loss has been associated with poorer recovery of
motor function (Dittmar et al., 2003). This could explain why we
found that, by comparing the two ALA supplementations, only oral
supplementation (achieved through the modiﬁcation of the daily
diet) improved motor recovery post-MCAo, while no dissimilarities
were found in infarct size and caudate-putamen lesion. Several
studies on basal ganglia dysfunction have implicated the putamen
in the control of motor coordination: these include motor learning,
motor performance and tasks, motor preparation, specifyingsults were obtained in the pole test that only showed an improvement of balance and
(n ¼ 15 per group at each time point). *p < 0.05 versus respective control, #p < 0.05;
p < 0.001). (E) Representative photographs of NeuN immunohistochemistry performed
antiﬁcation of NeuN þ cells conﬁrmed that the neuronal loss conﬁned to striatum and
provement in motor function by the ALA-diet is not correlated to any preservation of
r group). **p < 0.001 versus respective contralateral hemisphere. Scale bar is 50 mm,
Fig. 3. ALA-Diet improves post-MACo cognitive recovery evaluated by the Morris water-maze test. Between the 14 and 17 days after stroke, while no signiﬁcant difference were
found in the swimming speed (A) and the distance traveled (B), the time to reach the hidden platform (C) of the mice fed the ALA-diet was improved as compared to those fed the
regular diet. In addition to displaying a better learning, the mice fed the ALA-diet also showed a better recovery of spatial memory 18 days post-MCAo, as indicated by an increased
time spend in the target quadrant (D) and number of target crossings than the regular-diet group (E). (F) Representative swim patterns 18 days post-stroke illustrate the better
probe strategy of the mice fed the ALA-diet. (G). In the cue test performed the following day after for controlling the absence of visio-motor deﬁcits, the time to reach the visible
platformwas similar between the mice fed the ALA-and regular diet. Data are represented by mean ± SEM (n ¼ 15 per group). *p < 0.05 versus regular diet and ($) indicates a group
effect ($$p < 0.05) during the learning period.
Fig. 4. ALA subchronic i.v. treatment also improves post-MACo cognitive recovery. (A) Between the 14 and 17 days after stroke, ALA-subchronic treatment post-MCAo improves
the time to reach the hidden platform as compared to vehicle. (B) The mice injected with the subchronic treatment also displayed a better recovery of spatial memory 18 days post-
MCAo, as indicated by an increased time spent in the target quadrant. (C) Representative swim patterns 18 days post-stroke illustrate the better probe strategy of the mice fed the
ALA-diet. Data are represented by mean ± SEM (n ¼ 15 per group). *p < 0.05 versus vehicle and ($) indicates a group effect ($p < 0.05) during the learning period.
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Wise, 1984; Ward et al.). Nevertheless, in the present study the
ischemic damage does not seem to be involved in the difference of
motor recovery observed. Although we did not investigate whether
post-stroke metabolismwas improved by the ALA-diet, it is known
that stroke alters a number of metabolic factors and pathways due
to a global catabolic/anabolic imbalance. Indeed, the increased
catabolic and failing anabolic activities induce the depletion of
energy stores leading to muscle functional decline and fat wasting,
both of which contribute to the clinical manifestation of weight loss
(Gariballa et al., 1998). Indeed, lessons from “the obesity paradox”
suggesting that patients who are mildly obese may actually have a
better stroke outcome underline the requirement for monitoring
changes in body weight and composition after stroke. Treating the
catabolic/anabolic imbalance after stroke could signiﬁcantly
improve long-term outcome (Scherbakov et al., 2011). During short
periods of insufﬁcient energy supply, the human body will burn
primarily free fatty acids from body fat stores, and therefore willuse ALA as an energy source. Alpha-linolenic acid is integrally
involved in themetabolism and could interact directly with nuclear
receptors, such as peroxisome proliferator-activated receptor
(PPAR) (Forman et al., 1997), liver X receptor and hepatocyte nu-
clear factor-4 and therefore be implicated in glucose and lipid ho-
meostasis and for metabolic adaptation (Contreras et al., 2013).
Although further studies are required, it is tempting to conclude
that post-stroke nutritional support in ALA may be an important
and required source of energy and metabolic support that could
improve the short-term post-stroke body weight and motor
recovery.
Since 30 min MCAo in adult mice not only causes short-term
motor deﬁcits but also long-term impairment of the spatial
learning and memory, we evaluated the effect of ALA supplemen-
tation on spatial memory using the Morris water-maze task at 3
weeks after surgery, a time when MCAo animals display sponta-
neous recovery of body weight andmotor impairment (Freret et al.,
2011). Indeed, eventual secondary motor impairments and body
Fig. 5. ALA supplementation reduces parenchymal atrophy and loss of hippocampal neurons. (A and B) Twenty-one days post-MCAo, analysis of hemispheric volume identiﬁed a
substantial atrophy of the ipsilateral hemisphere compared to its contralateral in the control groups (e. g. regular diet fed and vehicle treated animals) that was circumvented by ALA
supplementation by consumption of ALA-diet or subchronic treatment. Data are represented by Boxes, median, and interquartile range; whiskers, minemax; þ, mean (n ¼ 6 per
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swimming speed did not differ between the different groups before
or after MCAo. Nevertheless, ALA-diet fed mice and ALA-injected
mice took signiﬁcantly less time and exhibited optimized search-
ing behaviors to reach the platform compared with themice fed the
regular diet or treated with the vehicle, respectively. These ﬁndings
demonstrate that nutritional support in omega-3 ALA achieved by
oral or intravenous supplementation improves the spontaneous
recovery of spatial learning and memory in a mouse model of
ischemic stroke.
Because the MWM is known to detect impairment in special
memory function associated with hippocampal damage (Morris
et al., 1982), we investigated the long-term damage speciﬁc to
this region. In the MCAo model used in this study, the cerebral
cortex was mostly spared and the striatum was infarcted. Here we
observed a correlation between hippocampal neurons loss and the
time spent in the target zone in the control groups (regular diet and
vehicle treated animals) suggesting that spatial cognitive impair-
ment in the MWM task could be correlated with the degree of
damage of the hippocampus. How MCAo induces brain lesions in
the hippocampus (this work) or thalamus and hypothalamus (Hata
et al., 1998), areas that are not directly supplied by the MCA, re-
mains unclear. Recently, Castel's group proposed that damage in
these deep regions might be due to the alteration of tissue perfu-
sion by deep and small cerebral arteries arising directly from the
internal carotid artery, at the proximity of the origin of MCA during
the intraluminal ﬁlament insertion (El Amki et al., 2015). Therefore,
vasoactive properties of ALA (Blondeau et al., 2007) could support
the anastomotic network, which supplies a part of the hippocam-
pus and the thalamus, and may participate in preservation of such
areas known to be crucial to spatial learning and memory. Both
types of ALA supplementation drastically reduce ischemic hemi-
sphere atrophy and ALA induces direct in vitro and in vivo neuro-
protective effects (Blondeau et al., 2001, 2002a; Heurteaux et al.,
2006; Lang-Lazdunski et al., 2003; Lauritzen et al., 2000; Ngue-
meni et al., 2010), likely accounting for reduced damaged pro-
jections from infarcted cortex, thalamic atrophy, or denervated
basal nucleus cholinergic ﬁbers to the cortex (Fujie et al., 1990;
Kataoka et al., 1991). Similarly, ALA protection from secondary
damage induced in neocortical sites within the MCA territory
known to also disturb spatial learning and memory independently
from hippocampal lesion (Frankland and Bontempi, 2005) could
account for the improvement of spatial learning and memory.
However the robust hippocampal protective effect of both types of
ALA supplementation against MCAo-induced hippocampal lesion
observed 3 weeks after the ischemic insult is undoubtedly a
determining factor in improving the recovery of MCAo-induced
deﬁcits identiﬁed in the MWM. The growing understanding of
the mechanisms that underlie recovery of the damage brain in-
volves neural plasticity (Kleim and Jones, 2008; Murphy and
Corbett, 2009). Therefore functional outcome may be improved
by restorative therapies through stimulation of synaptogenesis in
the ischemic brain (for review see (Chopp et al., 2009; Murphy and
Corbett, 2009)). Modiﬁcation of the omega-3 content of dietary
regimens change the genes brain expression of genes controlling
synaptic plasticity, cytoskeleton and membrane association, signalgroup). #p < 0.05 versus respective contralateral hemisphere, and *p < 0.05 versus respect
regular-diet and vehicle treated groups was signiﬁcantly reduced in the animal supplement
mean ± SEM (n ¼ 6 per group). *p < 0.05. (D) The better preservation of the hippocampal ne
layers. Scale bar is 100 mm, applicable to all sections. (E) A correlation that was analyzed by
zone was found in the control groups (regular diet and vehicle treated animals), conﬁrming
spatial memory recovery. The consumption of ALA-diet and the subchronic treatment did no
(F), the pre-MCAo omega-6/omega-3 ratio (G), and of saturated fatty acids (SFAs), mono unsa
per group).transduction, ion channel formation (Kitajka et al., 2002). We and
others have respectively shown that ALA injections and ALA-diet
triggered neurogenesis and synaptogenesis in the adult brain
(Blondeau et al., 2009a; Venna et al., 2009). Thus a casual rela-
tionship between ALA-induced synaptogenesis and cognitive re-
covery may be surmised. While the precise cellular and molecular
targets of ALA on stroke recovery will require further investigations
before being sorted out, an evident but under-studied link between
ALAeinduced protection and stroke recovery, that is cerebral
inﬂammation should be considered. Clinical and experimental ev-
idence have implicated cerebral inﬂammation in several aspects of
stroke: neuroinﬂammation may not only lead to irreversible
neuronal alterations, but probably contribute to worsen outcome
and recovery in stroke (Allan et al., 2005; Drake et al., 2011). In
contrast, several anti-inﬂammatory actions of omega-3 PUFAs have
been proposed, including in neonatal HypoxiceIschemic (H/I) brain
injury (Zhang et al., 2010). Indeed, Chen's laboratory has recently
shown that LC-omega-3 supplementation through an EPA/DHA-
enriched diet improves long-term neurological outcomes after
neonatal H/I injury. This prolonged protection was attributed to an
anti-inﬂammatory effect on microglia leading to a robust sup-
pression of proinﬂammatory mediator release (Zhang et al., 2010).
Our ongoing studies will determine whether suppression of neu-
roinﬂammation and release of proinﬂammatory cytokines (IL1-b,
IL-6, TNF-a) and chemokines (MCP-1, MIP-1-alpha, IL-8)
(Conductier et al., 2010; Le Thuc et al., 2015) play a critical role in
mediating the neuroprotective effect of ALA supplementation after
ischemic stroke.
With respect to efﬁciency of the oral and intravenous approach,
the overall beneﬁts of the subchronic treatment we used were less
impressive than those observed with the ALA-diet. Originally, this
subchronic treatment was only designed for promoting a better
survival against 60 min MCAo (Blondeau et al., 2009c; Heurteaux
et al., 2006). Therefore, such beneﬁcial effects on long-term hip-
pocampal and cognitive deﬁcits were unanticipated and since we
can not exclude that an optimization of subchronic treatment with
a daily delivery may offer results of similar amplitudes as the diet
enriched in ALA, it reinforces the idea that studies testing different
protocols and approaches are still needed in the ﬁeld.
5. Conclusions
In summary, in one of a minor number of studies concerning
nutritional intervention in the critically post-stroke recovery
period, we propose that nutritional intervention with ALA would
help counteract stroke-induced deﬁcits including impairments of
cognition that occur in patients (Stephens et al., 2004) This case for
nutritional support in ALA is also reinforced by the demonstration
of an association between hippocampus and memory in humans
(Burgess et al., 2002) and the correlation observed by MRI between
cognitive impairments to hippocampal alteration (Lin et al., 2014)
While insights into the precise mechanisms requires further
studies, we identify that hippocampal preservation has an intrinsic
effect of ALA treatment leading to reduced cognitive deﬁcits, which
is not due to bioconversion to DHA. Therefore, such work holds
promise as an instigator of further randomized, controlled studiesive control. (C) Neuronal loss observed in the hippocampus 21 days post-MCAo in the
ed in ALA by modiﬁcation of the diet or subchronic treatment. Data are represented by
urons is illustrated by representative cresyl violet staining of the CA1 and CA3 neuronal
Pearson's analysis between hippocampal neurons loss and the time spent in the target
why the ALA-supplemented animal presenting less hippocampal damage had a better
t modify in the cortex, the concentration of DHA, the major omega-3 PUFA of the brain
turated fatty acids (MUFAs) and PUFAs (H). Data are represented by mean ± SEM (n ¼ 5
M. Bourourou et al. / Neuropharmacology 108 (2016) 60e72 71that will be required to conﬁrm the value of ALA in adjunctive
therapy for one of medicine's most urgent priorities.
Funding sources
This work was supported by the CNRS, the Fondation pour la
Recherche Medicale DRM20101220421, ONIDOL (n889P00-01)
and St Hubert grants (n087696) and the SFNEP Bernard Beaufrere
Prize.
Disclosures
None.
Acknowledgments
We thank Dr C. Rovere, O. Le Thuc, C. Widmann, N. Simon-
Rousseau, C. Simonneau, A. Renault for many helpful discussions
and Dr J. Tauskela for his critical reading of the manuscript. We are
very grateful to Pr M. Guichardant and P. Daira (lipidomics IbiSA
platform of the LISA Carnot institute), and Drs N. Combe, L. Fonseca,
B. Buaud and C. Vaysse (Iterg, Equipe Nutrition, Metabolisme et
Sante) for Fatty Acid Analysis.
References
Allan, S.M., Tyrrell, P.J., Rothwell, N.J., 2005. Interleukin-1 and neuronal injury. Nat.
Rev. Immunol. 5, 629e640.
Aquilani, R., Scocchi, M., Iadarola, P., Viglio, S., Pasini, E., Condello, S., Boschi, F.,
Pastoris, O., Bongiorno, A.I., Verri, M., 2010. Spontaneous neurocognitive
retrieval of patients with sub-acute ischemic stroke is associated with dietary
protein intake. Nutr. Neurosci. 13, 129e134.
Awada, M., Meynier, A., Soulage, C.O., Hadji, L., Geloen, A., Viau, M., Ribourg, L.,
Benoit, B., Debard, C., Guichardant, M., Lagarde, M., Genot, C., Michalski, M.C.,
2013. n-3 PUFA added to high-fat diets affect differently adiposity and
inﬂammation when carried by phospholipids or triacylglycerols in mice. Nutr.
Metab. (Lond) 10, 23.
Balkaya, M., Krober, J.M., Rex, A., Endres, M., 2013. Assessing post-stroke behavior in
mouse models of focal ischemia. J. Cereb. Blood Flow. Metab. 33, 330e338.
Belayev, L., Khoutorova, L., Atkins, K.D., Eady, T.N., Hong, S., Lu, Y., Obenaus, A.,
Bazan, N.G., 2011. Docosahexaenoic acid therapy of experimental ischemic
stroke. Transl. Stroke Res. 2, 33e41.
Blondeau, N., 2016 Jan. The nutraceutical potential of omega-3 alpha-linolenic acid
in reducing the consequences of stroke. Biochimie 120, 49e55. http://
dx.doi.org/10.1016/j.biochi.2015.06.005.
Blondeau, N., Debruyne, D., Piens, M., Nguemeni, C., Plumier, J.C., Lipsky, R.H.,
Marini, A.M., Heurteaux, C., 2009a. Brain plasticity and anti-depressant effects
are versatile potential of alpha-linolenic acid to promote stroke recovery.
J. Cereb. Blood Flow Metabolism 29, S545.
Blondeau, N., Lauritzen, I., Widmann, C., Lazdunski, M., Heurteaux, C., 2002a.
A potent protective role of lysophospholipids against global cerebral ischemia
and glutamate excitotoxicity in neuronal cultures. J. Cereb. Blood Flow. Metab.
22, 821e834.
Blondeau, N., Lipsky, R.H., Bourourou, M., Duncan, M.W., Gorelick, P.B., Marini, A.M.,
2015. Alpha-linolenic acid: an omega-3 fatty acid with neuroprotective
properties-ready for use in the stroke clinic? Biomed. Res. Int. 2015, 519830.
Blondeau, N., Nguemeni, C., Debruyne, D.N., Piens, M., Wu, X., Pan, H., Hu, X.,
Gandin, C., Lipsky, R.H., Plumier, J.C., Marini, A.M., Heurteaux, C., 2009b. Sub-
chronic alpha-linolenic acid treatment enhances brain plasticity and exerts an
antidepressant effect: a versatile potential therapy for stroke. Neuro-
psychopharmacology 34, 2548e2559.
Blondeau, N., Nguemeni, C., Debruyne, D.N., Piens, M., Wu, X., Pan, H., Hu, X.,
Gandin, C., Lipsky, R.H., Plumier, J.C., Marini, A.M., Heurteaux, C., 2009c. Sub-
chronic alpha-linolenic acid treatment enhances brain plasticity and exerts an
antidepressant effect: a versatile potential therapy for stroke. Neuro-
psychopharmacology 34, 2548e2559.
Blondeau, N., Petrault, O., Manta, S., Giordanengo, V., Gounon, P., Bordet, R.,
Lazdunski, M., Heurteaux, C., 2007. Polyunsaturated fatty acids are cerebral
vasodilators via the TREK-1 potassium channel. Circ. Res. 101, 176e184.
Blondeau, N., Tauskela, J.S., 2013. A new future in brain preconditioning based on
nutraceuticals: a focus on a-linolenic omega-3 fatty acid for stroke protection.
In: Gidday, J.M., Perez-Pinzon, M.A., Zhang, J.H. (Eds.), Innate Tolerance in the
CNS. Springer New York, New York, pp. 133e163.
Blondeau, N., Widmann, C., Lazdunski, M., Heurteaux, C., 2001. Activation of the
nuclear factor-kappaB is a key event in brain tolerance. J. Neurosci. 21,
4668e4677.
Blondeau, N., Widmann, C., Lazdunski, M., Heurteaux, C., 2002b. Polyunsaturatedfatty acids induce ischemic and epileptic tolerance. Neuroscience 109, 231e241.
Blondeau, N., Widmann, C., Lazdunski, M., Heurteaux, C., 2003. Activation of the
nuclear factor-kappaB is a key event in brain tolerance. In: Krieglstein, J.,
Klumpp, S. (Eds.), Pharmacology of Cerebral Ischemia. Medpharm Scientiﬁc
Publishers, Stuttgart.
Bourre, J.M., Dumont, O., Pascal, G., Durand, G., 1993. Dietary alpha-linolenic acid at
1.3 g/kg maintains maximal docosahexaenoic acid concentration in brain, heart
and liver of adult rats. J. Nutr. 123, 1313e1319.
Burgess, N., Maguire, E.A., O'Keefe, J., 2002. The human hippocampus and spatial
and episodic memory. Neuron 35, 625e641.
Calautti, C., Baron, J.C., 2003. Functional neuroimaging studies of motor recovery
after stroke in adults: a review. Stroke 34, 1553e1566.
Chopp, M., Li, Y., Zhang, Z.G., 2009. Mechanisms underlying improved recovery of
neurological function after stroke in the rodent after treatment with neuro-
restorative cell-based therapies. Stroke 40, S143eS145.
Collaboration, F.T., 2003. Poor nutritional status on admission predicts poor out-
comes after stroke: observational data from the FOOD trial. Stroke 34,
1450e1456.
Conductier, G., Blondeau, N., Guyon, A., Nahon, J.L., Rovere, C., 2010. The role of
monocyte chemoattractant protein MCP1/CCL2 in neuroinﬂammatory diseases.
J. Neuroimmunol. 224, 93e100.
Contreras, A.V., Torres, N., Tovar, A.R., 2013. PPAR-alpha as a key nutritional and
environmental sensor for metabolic adaptation. Adv. Nutr. 4, 439e452.
Cramer, S.C., 2008. Repairing the human brain after stroke. II. Restorative therapies.
Ann. Neurol. 63, 549e560.
Cumming, T.B., Marshall, R.S., Lazar, R.M., 2013. Stroke, cognitive deﬁcits, and
rehabilitation: still an incomplete picture. Int. J. Stroke 8, 38e45.
Dennis, M.S., Lewis, S.C., Warlow, C., Collaboration, F.T., 2005. Routine oral nutri-
tional supplementation for stroke patients in hospital (FOOD): a multicentre
randomised controlled trial. Lancet 365, 755e763.
Di Pino, G., Pellegrino, G., Assenza, G., Capone, F., Ferreri, F., Formica, D., Ranieri, F.,
Tombini, M., Ziemann, U., Rothwell, J.C., Di Lazzaro, V., 2014. Modulation of
brain plasticity in stroke: a novel model for neurorehabilitation. Nat. Rev.
Neurol. 10, 597e608.
Dittmar, M., Spruss, T., Schuierer, G., Horn, M., 2003. External carotid artery territory
ischemia impairs outcome in the endovascular ﬁlament model of middle ce-
rebral artery occlusion in rats. Stroke 34, 2252e2257.
Drake, C., Boutin, H., Jones, M.S., Denes, A., McColl, B.W., Selvarajah, J.R., Hulme, S.,
Georgiou, R.F., Hinz, R., Gerhard, A., Vail, A., Prenant, C., Julyan, P., Maroy, R.,
Brown, G., Smigova, A., Herholz, K., Kassiou, M., Crossman, D., Francis, S.,
Proctor, S.D., Russell, J.C., Hopkins, S.J., Tyrrell, P.J., Rothwell, N.J., Allan, S.M.,
2011. Brain inﬂammation is induced by co-morbidities and risk factors for
stroke. Brain Behav. Immun. 25, 1113e1122.
El Amki, M., Clavier, T., Perzo, N., Bernard, R., Guichet, P.O., Castel, H., 2015. Hypo-
thalamic, thalamic and hippocampal lesions in the mouse MCAO model: po-
tential involvement of deep cerebral arteries? J. Neurosci. Methods 254, 80e85.
Evarts, E.V., Wise, S.P., 1984. Basal ganglia outputs and motor control. Ciba Found.
Symp. 107, 83e102.
Forman, B.M., Chen, J., Evans, R.M., 1997. Hypolipidemic drugs, polyunsaturated
fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated
receptors alpha and delta. Proc. Natl. Acad. Sci. U. S. A. 94, 4312e4317.
Frankland, P.W., Bontempi, B., 2005. The organization of recent and remote mem-
ories. Nat. Rev. Neurosci. 6, 119e130.
Freret, T., Schumann-Bard, P., Boulouard, M., Bouet, V., 2011. On the importance of
long-term functional assessment after stroke to improve translation from
bench to bedside. Exp. Transl. Stroke Med. 3, 6.
Fujie, W., Kirino, T., Tomukai, N., Iwasawa, T., Tamura, A., 1990. Progressive
shrinkage of the thalamus following middle cerebral artery occlusion in rats.
Stroke 21, 1485e1488.
Gariballa, S.E., Parker, S.G., Taub, N., Castleden, C.M., 1998. Inﬂuence of nutritional
status on clinical outcome after acute stroke. Am. J. Clin. Nutr. 68, 275e281.
Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., Dai, S.,
Ford, E.S., Fox, C.S., Franco, S., Fullerton, H.J., Gillespie, C., Hailpern, S.M.,
Heit, J.A., Howard, V.J., Huffman, M.D., Judd, S.E., Kissela, B.M., Kittner, S.J.,
Lackland, D.T., Lichtman, J.H., Lisabeth, L.D., Mackey, R.H., Magid, D.J.,
Marcus, G.M., Marelli, A., Matchar, D.B., McGuire, D.K., Mohler 3rd, E.R.,
Moy, C.S., Mussolino, M.E., Neumar, R.W., Nichol, G., Pandey, D.K., Paynter, N.P.,
Reeves, M.J., Sorlie, P.D., Stein, J., Towﬁghi, A., Turan, T.N., Virani, S.S.,
Wong, N.D., Woo, D., Turner, M.B., 2014. Executive summary: heart disease and
stroke statisticse2014 update: a report from the American Heart Association.
Circulation 129, 399e410.
Golanov, E.V., Reis, D.J., 1995. Contribution of cerebral edema to the neuronal
salvage elicited by stimulation of cerebellar fastigial nucleus after occlusion of
the middle cerebral artery in rat. J. Cereb. Blood Flow. Metab. 15, 172e174.
Gouix, E., Buisson, A., Nieoullon, A., Kerkerian-Le Goff, L., Tauskela, J.S., Blondeau, N.,
Had-Aissouni, L., 2014. Oxygen glucose deprivation-induced astrocyte
dysfunction provokes neuronal death through oxidative stress. Pharmacol. Res.
87, 8e17.
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R.,
Ekman, M., Faravelli, C., Fratiglioni, L., Gannon, B., Jones, D.H., Jennum, P.,
Jordanova, A., Jonsson, L., Karampampa, K., Knapp, M., Kobelt, G., Kurth, T.,
Lieb, R., Linde, M., Ljungcrantz, C., Maercker, A., Melin, B., Moscarelli, M.,
Musayev, A., Norwood, F., Preisig, M., Pugliatti, M., Rehm, J., Salvador-Carulla, L.,
Schlehofer, B., Simon, R., Steinhausen, H.C., Stovner, L.J., Vallat, J.M., Van den
Bergh, P., van Os, J., Vos, P., Xu, W., Wittchen, H.U., Jonsson, B., Olesen, J.,
M. Bourourou et al. / Neuropharmacology 108 (2016) 60e7272Group, C.D., 2011. Cost of disorders of the brain in Europe 2010. Eur. Neuro-
psychopharmacol. 21, 718e779.
Hankey, G.J., 2012. Nutrition and the risk of stroke. Lancet Neurol. 11, 66e81.
Hata, R., Mies, G., Wiessner, C., Fritze, K., Hesselbarth, D., Brinker, G.,
Hossmann, K.A., 1998. A reproducible model of middle cerebral artery occlusion
in mice: hemodynamic, biochemical, and magnetic resonance imaging. J. Cereb.
Blood Flow. Metab. 18, 367e375.
Heller, A.R., Fischer, S., Rossel, T., Geiger, S., Siegert, G., Ragaller, M., Zimmermann, T.,
Koch, T., 2002. Impact of n-3 fatty acid supplemented parenteral nutrition on
haemostasis patterns after major abdominal surgery. Br. J. Nutr. 87 (Suppl. 1),
S95eS101.
Heller, A.R., Rossler, S., Litz, R.J., Stehr, S.N., Heller, S.C., Koch, R., Koch, T., 2006.
Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit. Care
Med. 34, 972e979.
Heurteaux, C., Laigle, C., Blondeau, N., Jarretou, G., Lazdunski, M., 2006. Alpha-
linolenic acid and riluzole treatment confer cerebral protection and improve
survival after focal brain ischemia. Neuroscience 137, 241e251.
Ji, S., Kronenberg, G., Balkaya, M., Farber, K., Gertz, K., Kettenmann, H., Endres, M.,
2009. Acute neuroprotection by pioglitazone after mild brain ischemia without
effect on long-term outcome. Exp. Neurol. 216, 321e328.
Johansson, B.B., 2011. Current trends in stroke rehabilitation. A review with focus on
brain plasticity. Acta Neurol. Scand. 123, 147e159.
Johnston, S.C., Mendis, S., Mathers, C.D., 2009. Global variation in stroke burden and
mortality: estimates from monitoring, surveillance, and modelling. Lancet
Neurol. 8, 345e354.
Jonsson, A.C., Lindgren, I., Norrving, B., Lindgren, A., 2008. Weight loss after stroke:
a population-based study from the Lund Stroke Register. Stroke 39, 918e923.
Jorgensen, H.S., Nakayama, H., Raaschou, H.O., Olsen, T.S., 1995. Recovery of walking
function in stroke patients: the Copenhagen Stroke Study. Arch. Phys. Med.
Rehabil. 76, 27e32.
Kataoka, K., Hayakawa, T., Kuroda, R., Yuguchi, T., Yamada, K., 1991. Cholinergic
deafferentation after focal cerebral infarct in rats. Stroke 22, 1291e1296.
Katchanov, J., Harms, C., Gertz, K., Hauck, L., Waeber, C., Hirt, L., Priller, J., von
Harsdorf, R., Bruck, W., Hortnagl, H., Dirnagl, U., Bhide, P.G., Endres, M., 2001.
Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and
activation of cell cycle machinery before delayed neuronal cell death.
J. Neurosci. 21, 5045e5053.
Katchanov, J., Waeber, C., Gertz, K., Gietz, A., Winter, B., Bruck, W., Dirnagl, U.,
Veh, R.W., Endres, M., 2003. Selective neuronal vulnerability following mild
focal brain ischemia in the mouse. Brain Pathol. 13, 452e464.
Kilic, E., ElAli, A., Kilic, U., Guo, Z., Ugur, M., Uslu, U., Bassetti, C. L., Schwab, M. E.,
Hermann, D. M., Role of Nogo-A in neuronal survival in the reperfused ischemic
brain. J. Cereb. Blood Flow. Metab. 30, 969e984.
Kitajka, K., Puskas, L.G., Zvara, A., Hackler Jr., L., Barcelo-Coblijn, G., Yeo, Y.K.,
Farkas, T., 2002. The role of n-3 polyunsaturated fatty acids in brain: modula-
tion of rat brain gene expression by dietary n-3 fatty acids. Proc. Natl. Acad. Sci.
U. S. A. 99, 2619e2624.
Kleim, J.A., Jones, T.A., 2008. Principles of experience-dependent neural plasticity:
implications for rehabilitation after brain damage. J. Speech Lang. Hear Res. 51,
S225eS239.
Kris-Etherton, P.M., Harris, W.S., Appel, L.J., 2002. Fish consumption, ﬁsh oil, omega-
3 fatty acids, and cardiovascular disease. Circulation 106, 2747e2757.
Lang-Lazdunski, L., Blondeau, N., Jarretou, G., Lazdunski, M., Heurteaux, C., 2003.
Linolenic acid prevents neuronal cell death and paraplegia after transient spinal
cord ischemia in rats. J. Vasc. Surg. 38, 564e575.
Langhorne, P., Bernhardt, J., Kwakkel, G., 2011. Stroke rehabilitation. Lancet 377,
1693e1702.
Langhorne, P., Coupar, F., Pollock, A., 2009. Motor recovery after stroke: a systematic
review. Lancet Neurol. 8, 741e754.
Lauritzen, I., Blondeau, N., Heurteaux, C., Widmann, C., Romey, G., Lazdunski, M.,
2000. Polyunsaturated fatty acids are potent neuroprotectors. Embo J. 19,
1784e1793.
Le Thuc, O., Blondeau, N., Nahon, J.L., Rovere, C., 2015 Sep. The complex contribution
of chemokines to neuroinﬂammation: switching from beneﬁcial to detrimental
effects. Ann. N. Y. Acad. Sci. 1351, 127e140. http://dx.doi.org/10.1111/nyas.12855.
Lee, J.H., Zheng, Y., von Bornstadt, D., Wei, Y., Balcioglu, A., Daneshmand, A.,
Yalcin, N., Yu, E., Herisson, F., Atalay, Y.B., Kim, M.H., Ahn, Y.J., Balkaya, M.,
Sweetnam, P., Schueller, O., Poyurovsky, M.V., Kim, H.H., Lo, E.H., Furie, K.L.,
Ayata, C., 2014. Selective ROCK2 inhibition in focal cerebral ischemia. Ann. Clin.Transl. Neurol. 1, 2e14.
Lin, Z.C., Tao, J., Gao, Y.L., Yin, D.Z., Chen, A.Z., Chen, L.D., 2014. Analysis of central
mechanism of cognitive training on cognitive impairment after stroke: resting-
state functional magnetic resonance imaging study. J. Int. Med. Res. 42,
659e668.
Lincoln, N.B., Majid, M.J., Weyman, N., 2000. Cognitive rehabilitation for attention
deﬁcits following stroke. Cochrane Database Syst. Rev. 4. CD002842.
Lloyd-Jones, D., Adams, R.J., Brown, T.M., Carnethon, M., Dai, S., De Simone, G.,
Ferguson, T.B., Ford, E., Furie, K., Gillespie, C., Go, A., Greenlund, K., Haase, N.,
Hailpern, S., Ho, P.M., Howard, V., Kissela, B., Kittner, S., Lackland, D., Lisabeth, L.,
Marelli, A., McDermott, M.M., Meigs, J., Mozaffarian, D., Mussolino, M.,
Nichol, G., Roger, V.L., Rosamond, W., Sacco, R., Sorlie, P., Thom, T., Wasserthiel-
Smoller, S., Wong, N.D., Wylie-Rosett, J., 2010. Heart disease and stroke
statisticse2010 update: a report from the American Heart Association. Circu-
lation 121, e46ee215.
Matsuura, K., Kabuto, H., Makino, H., Ogawa, N., 1997. Pole test is a useful method
for evaluating the mouse movement disorder caused by striatal dopamine
depletion. J. Neurosci. Methods 73, 45e48.
Morris, R.G., Garrud, P., Rawlins, J.N., O'Keefe, J., 1982. Place navigation impaired in
rats with hippocampal lesions. Nature 297, 681e683.
Murphy, T.H., Corbett, D., 2009. Plasticity during stroke recovery: from synapse to
behaviour. Nat. Rev. Neurosci. 10, 861e872.
Nair, R.D., Lincoln, N.B., 2007 Jul 18. Cognitive rehabilitation for memory deﬁcits
following stroke. Cochrane Database Syst. Rev. 3. CD002293.
Nguemeni, C., Delplanque, B., Rovere, C., Simon-Rousseau, N., Gandin, C., Agnani, G.,
Nahon, J.L., Heurteaux, C., Blondeau, N., 2010. Dietary supplementation of
alpha-linolenic acid in an enriched rapeseed oil diet protects from stroke.
Pharmacol. Res. 61, 226e233.
Nguemeni, C., Gouix, E., Bourourou, M., Heurteaux, C., Blondeau, N., 2013. Alpha-
linolenic acid: a promising nutraceutical for the prevention of stroke. Phar-
maNutrition 1, 1e8.
Pilz, S., Tomaschitz, A., Drechsler, C., Zittermann, A., Dekker, J.M., Marz, W., 2011.
Vitamin D supplementation: a promising approach for the prevention and
treatment of strokes. Curr. Drug Targets 12, 88e96.
Plamondon, H., Roberge, M.C., 2008. Dietary PUFA supplements reduce memory
deﬁcits but not CA1 ischemic injury in rats. Physiol. Behav. 95, 492e500.
Pudelkewicz, C., Seufert, J., Holman, R.T., 1968. Requirements of the female rat for
linoleic and linolenic acids. J. Nutr. 94, 138e146.
Quintard, H., Borsotto, M., Veyssiere, J., Gandin, C., Labbal, F., Widmann, C.,
Lazdunski, M., Heurteaux, C., 2011. MLC901, a traditional Chinese medicine
protects the brain against global ischemia. Neuropharmacology 61, 622e631.
Rehni, A.K., Singh, T.G., 2012. Involvement of CCR-2 chemokine receptor activation
in ischemic preconditioning and postconditioning of brain in mice. Cytokine 60,
83e89.
Riediger, N.D., Othman, R.A., Suh, M., Moghadasian, M.H., 2009. A systemic review
of the roles of n-3 fatty acids in health and disease. J. Am. Diet. Assoc. 109,
668e679.
Rogers, D.C., Campbell, C.A., Stretton, J.L., Mackay, K.B., 1997. Correlation between
motor impairment and infarct volume after permanent and transient middle
cerebral artery occlusion in the rat. Stroke 28, 2060e2065 discussion 2066.
Scherbakov, N., Dirnagl, U., Doehner, W., 2011. Body weight after stroke: lessons
from the obesity paradox. Stroke 42, 3646e3650.
Stephens, S., Kenny, R.A., Rowan, E., Allan, L., Kalaria, R.N., Bradbury, M., Ballard, C.G.,
2004. Neuropsychological characteristics of mild vascular cognitive impairment
and dementia after stroke. Int. J. Geriatr. Psychiatry 19, 1053e1057.
Strong, K., Mathers, C., Bonita, R., 2007. Preventing stroke: saving lives around the
world. Lancet Neurol. 6, 182e187.
Venna, V.R., Deplanque, D., Allet, C., Belarbi, K., Hamdane, M., Bordet, R., 2009. PUFA
induce antidepressant-like effects in parallel to structural and molecular
changes in the hippocampus. Psychoneuroendocrinology 34, 199e211.
Ward, P., Seri, Cavanna, A. E., Functional neuroanatomy and behavioural correlates
of the basal ganglia: evidence from lesion studies. Behav. Neurol. 26, 219e223.
Winter, B., Bert, B., Fink, H., Dirnagl, U., Endres, M., 2004. Dysexecutive syndrome
after mild cerebral ischemia? Mice learn normally but have deﬁcits in strategy
switching. Stroke 35, 191e195.
Zhang, W., Hu, X., Yang, W., Gao, Y., Chen, J., 2010. Omega-3 polyunsaturated fatty
acid supplementation confers long-term neuroprotection against neonatal
hypoxic-ischemic brain injury through anti-inﬂammatory actions. Stroke 41,
2341e2347.
